Tuesday, July 24, 2012

Afinitor Approved for HR+ve breast cancer - Biocon to benefit

Biocon is the only Indian company to have launched a generic version of Afinitor in India and is sold under  the brand name Evertor.  A couple of days back, Afinitor received approval from the USFDA for the  treatment of HR+ve breast cancer.  The approval is based on breakthrough survival benefit (Median PFS was 11 months versus 4.1months with exemestane alone) demonstrated by Afinitor in patients with HR+ve and HER2-ve breast cancer  who have previously failed  Letrozole/Anastrazole therapy.    The global market  potential for this indication for Afinitor is $1.5billion. Assuming a 95% discount to Afinitor price for Evertor in India, the drug may potentially fetch an incremental 100 cr for  Biocon in incremental revenues